Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would ...

Telehealth company Hims & Hers on Monday announced a “strategic shift” in its business model, partnering with pharmaceutical ...

After years of fighting over compounded weight loss drugs, Hims & Hers and Novo Nordisk are teaming up to sell Ozempic and Wegovy — a shift that could raise costs for patients.

Drug executives say only their GLP-1 drugs are safe for treating obesity and diabetes as they wage a year-long campaign to ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent ...

Add Yahoo as a preferred source to see more of our stories on Google. Wegovy and other injectable weight-loss medications have soared in popularity in the past two years. Supply issues and spotty ...

The agreement brings an end to the legal dispute between the two companies. Hims & Hers shares jumped.

Especially in women’s health, this former regulatory gray area could help patients who have waited too long for FDA-approved ...

The Food and Drug Administration’s crackdown on cheaper, independently produced versions of popular weight-loss and diabetes medications stoked anger and pushback from users, sellers and the Alliance ...

The FDA issued warning letters to 30 telehealth companies over misleading claims about compounded versions of popular weight-loss drugs like Ozempic and Zepbound.

March 3 (Reuters) - The U.S. Food and Drug Administration has issued warning letters to 30 telehealth companies for making ...

A Kentucky lawmaker has filed a new bill that would strengthen oversight of compounded drugs, including weight loss ...